Clinical trials
Patients With Advanced Solid Tumors clinical trials
Below are recruiting patients with advanced solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,036 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06409065Recruiting
Emotional and spiritual support for advanced cancer and caregivers
This study offers a program to help people with advanced cancer and their caregivers cope with emotional and spiritual distress. It involves talking with a counselor together to improve your well-being.
Houston, TexasAges 18 years+ - NCT05950139RecruitingPhase 1/Phase 2
Vaccine to help stop lung cancer drug resistance
This early-phase study tests a personalized peptide vaccine designed to help prevent advanced ALK-positive non-small cell lung cancer from developing resistance to current targeted medicines. If you are stable on an ALK drug and don’t already have the specific resistance changes the vaccine targets, it may help your cancer stay controlled longer.
Baltimore, MarylandAges 18 years+ - NCT05482893RecruitingPhase 1/Phase 2
Study of spevatamig for advanced gastrointestinal cancers
This trial tests a new drug called spevatamig (PT886) alone or with other treatments for advanced stomach, gastric, pancreatic, bile duct, or colorectal cancers. The goal is to see if it helps slow or stop cancer growth.
Duarte, CaliforniaAges 18 years+ - NCT05365659RecruitingPhase 1
Testing IKS03 for advanced B-cell lymphoma
This trial tests a new study drug, IKS03, for people with advanced B-cell non-Hodgkin lymphoma that has not responded to at least two prior treatments. The goal is to see if the drug is safe and how well it works.
Baltimore, MarylandAges 18 years+ - NCT04995003RecruitingPhase 1
HER2 CAR T plus pembrolizumab for advanced HER2 sarcoma
This Phase 1 study tests a personalized immune-cell treatment (HER2 CAR T cells) given with an immune “checkpoint” medicine (pembrolizumab or another checkpoint blocker) to shrink advanced HER2-positive sarcoma. It may help patients whose cancer is progressing or coming back after prior treatment.
Houston, TexasAges 1–25 - NCT03514368Recruiting
Testing immune markers to track cancer treatment safety and benefit
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
ToulouseAges 18 years+ - NCT06825546RecruitingPhase 2
Icaritin plus chemo for advanced pancreatic cancer
This trial tests a new combination of a plant-based drug (icaritin) and two chemotherapy drugs (AG) for people with advanced pancreatic cancer who have not had treatment before. The goal is to see if the combination works better than chemotherapy alone.
Guangzhou, GuangdongAges 18–80 - NCT06006013RecruitingPhase 2
Cabozantinib and pembrolizumab for adrenal cancer
This trial tests a combination of two drugs (cabozantinib and pembrolizumab) for adrenal cancer that has spread or cannot be removed by surgery. It may be an option if you have not had treatment before or have already tried other therapies.
Atlanta, GeorgiaAges 18 years+ - NCT07544056RecruitingPhase 2/Phase 3
BEBT-209 Plus Chemotherapy for Triple-Negative Breast Cancer
This study tests a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) in women with advanced triple-negative breast cancer that has spread or cannot be surgically removed. The goal is to see if this combination can slow or stop cancer growth better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT06995105RecruitingPhase 1/Phase 2
Personalized mRNA Vaccine for Advanced Liver Cancer
This trial tests a personalized mRNA vaccine made from your tumor's unique genetic markers. It is for people with advanced liver cancer who have not yet received any treatment.
Hangzhou, ZhejiangAges 18–75 - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune disease
This trial tests whether the immunotherapy drug nivolumab can safely treat advanced cancer in people who also have an autoimmune disease like rheumatoid arthritis, lupus, or multiple sclerosis. It aims to find out if the drug may help control cancer while managing their autoimmune condition.
Birmingham, AlabamaAges 18 years+ - NCT07483983RecruitingPhase 2
Study of ASP3082 for advanced lung and pancreatic cancers with KRAS G12D mutation
This trial tests a new drug, ASP3082, for people with advanced non-small cell lung cancer or pancreatic cancer that has a specific gene change called KRAS G12D. The study will collect tumor and blood samples to understand how the cancer responds or becomes resistant to the treatment.
Villejuif, FranceAges 18 years+ - NCT07016230RecruitingPhase 2
Study of tarlatamab for small-cell lung cancer and other neuroendocrine cancers
This trial tests a new drug, tarlatamab, which targets a protein called DLL3 found on the surface of certain cancer cells. The goal is to see if it can shrink or control tumors in people with small-cell lung cancer or other poorly differentiated neuroendocrine cancers, and to learn more about who benefits most.
BordeauxAges 18 years+ - NCT05382728RecruitingPhase 3
Test drug for EGFR-mutant lung cancer without prior treatment
This Phase 3 trial studies TY-9591 in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR gene changes. It’s for those who haven’t had earlier medicines for advanced lung cancer, and it aims to see if the drug works better or safer than the comparison treatment.
Changsha, HunanAges 18–80 - NCT05280314RecruitingPhase 2
Immunotherapy before and after surgery for stage III melanoma or throat cancer
This trial tests two immunotherapy medicines given before surgery and again after surgery to help control the cancer and improve outcomes. It studies people with resectable (operable) stage III melanoma or certain stage III/IVA throat cancers.
New Haven, ConnecticutAges 18 years+ - NCT06749886RecruitingPhase 2
Tislelizumab plus chemo for advanced lung cancer after prior immunotherapy
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
ShanghaiAges 18 years+ - NCT06793813RecruitingPhase 2
Study of cadonilimab for advanced lung cancer
This trial tests a new drug called cadonilimab for people with advanced non-squamous non-small cell lung cancer that has gotten worse after treatment with immunotherapy and chemotherapy. The goal is to see if it helps control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07416994RecruitingPhase 3
Study of YL202 vs. docetaxel for advanced EGFR-mutant lung cancer
This trial tests a new drug, YL202, against a standard chemotherapy (docetaxel) for people with a specific type of advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if YL202 works better for those whose cancer has progressed after prior treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06620848RecruitingPhase 2
A trial of HRS-4642 alone or with adebrelimab for advanced bile duct cancer
This trial tests a new drug, HRS-4642, either by itself or combined with another drug called adebrelimab, for people whose advanced bile duct cancer has come back or gotten worse after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Denver, ColoradoAges 18 years+ - NCT05862259Recruiting
Immunotherapy as first treatment for advanced stage IV cancers
This study looks at whether immune checkpoint inhibitors given as the first treatment work well and are safe for people with advanced (stage IV) solid tumors. You might qualify if you can take study treatment reliably and your cancer type and health match the study rules.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06795022RecruitingPhase 1/Phase 2
Testing AZD9793 for advanced solid tumors with GPC3
This trial is testing a new medicine, AZD9793, for people with advanced or metastatic solid tumors that have a specific marker called GPC3. The goal is to see if AZD9793 can help shrink or control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT04852328RecruitingPhase 2
Testing CUE-101 schedules before treatment for HPV16 throat cancer
This Phase 2 trial studies different timing “schedules” of CUE-101 given before surgery or before chemoradiation for HPV16-positive oropharyngeal throat cancer. The goal is to see if CUE-101 can help the body respond better and potentially improve outcomes.
St Louis, MissouriAges 18 years+ - NCT06064812RecruitingPhase 1/Phase 2
Testing a new drug for advanced ER-positive breast cancer
This trial tests an experimental oral drug (FWD1802) for women with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to hormone therapy. It looks at whether the drug can slow or stop cancer growth, especially if you have an ESR1 mutation.
Hefei, AnhuiAges 18 years+
Hear when a new Patients With Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patients with advanced solid tumors?
- Yes. Clin2 currently lists 1,036 recruiting patients with advanced solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patients with advanced solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patients with advanced solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Advanced Solid Tumor
- Advanced Malignant Solid Neoplasm
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.